These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24753957)

  • 21. Oral contraceptives: a reassessment.
    Derman R
    Obstet Gynecol Surv; 1989 Sep; 44(9):662-8. PubMed ID: 2671844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pill and cancer: a review of the literature. A case of swings and roundabouts?
    Knowlden HA
    J Adv Nurs; 1990 Sep; 15(9):1016-20. PubMed ID: 2229699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention.
    Dilley SE; Havrilesky LJ; Bakkum-Gamez J; Cohn DE; Michael Straughn J; Caughey AB; Rodriguez MI
    Gynecol Oncol; 2017 Aug; 146(2):373-379. PubMed ID: 28577884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use.
    Wu ML; Whittemore AS; Paffenbarger RS; Sarles DL; Kampert JB; Grosser S; Jung DL; Ballon S; Hendrickson M; Mohle-Boetani J
    Am J Epidemiol; 1988 Dec; 128(6):1216-27. PubMed ID: 3195563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer.
    Ness RB; Grisso JA; Cottreau C; Klapper J; Vergona R; Wheeler JE; Morgan M; Schlesselman JJ
    Epidemiology; 2000 Mar; 11(2):111-7. PubMed ID: 11021606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for epithelial ovarian cancer in Beijing, China.
    Chen Y; Wu PC; Lang JH; Ge WJ; Hartge P; Brinton LA
    Int J Epidemiol; 1992 Feb; 21(1):23-9. PubMed ID: 1544753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Examining indicators of early menopause following opportunistic salpingectomy: a cohort study from British Columbia, Canada.
    Hanley GE; Kwon JS; McAlpine JN; Huntsman DG; Finlayson SJ; Miller D
    Am J Obstet Gynecol; 2020 Aug; 223(2):221.e1-221.e11. PubMed ID: 32067967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal ultrasonographic study of the ovarian suppressive activity of a low-dose triphasic oral contraceptive during correct and incorrect pill intake.
    Hamilton CJ; Hoogland HJ
    Am J Obstet Gynecol; 1989 Nov; 161(5):1159-62. PubMed ID: 2686444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function.
    Petta CA; Faúndes A; Dunson TR; Ramos M; DeLucio M; Faúndes D; Bahamondes L
    Fertil Steril; 1998 Nov; 70(5):817-20. PubMed ID: 9806559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis.
    Tung KH; Wilkens LR; Wu AH; McDuffie K; Nomura AM; Kolonel LN; Terada KY; Goodman MT
    Am J Epidemiol; 2005 Feb; 161(4):321-9. PubMed ID: 15692075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ovarian activity during regular oral contraceptive use.
    Crosignani PG; Testa G; Vegetti W; Parazzini F
    Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenging Salpingectomy as a Risk-Reducing Measure for Ovarian Cancer: Histopathological Analysis of the Tubo-Ovarian Interface in Women Undergoing Risk-Reducing Salpingo-oophorectomy.
    Ayres C; Ratnayake G; McNally O; Quinn M
    Int J Gynecol Cancer; 2017 May; 27(4):703-707. PubMed ID: 28399030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Canadian Contraception Consensus (Part 2 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N
    J Obstet Gynaecol Can; 2015 Nov; 37(11):1033-9. PubMed ID: 26629725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Canadian Contraception Consensus (Part 1 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N;
    J Obstet Gynaecol Can; 2015 Oct; 37(10):936-42. PubMed ID: 26606712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of different doses of norethisterone on ovarian function, serum sex hormone binding globulin and high density lipoprotein-cholesterol.
    Song S; Chen JK; Lu CH; Yang PJ; Yang QY; Fan BC; He ML; Gui YL; Li LM; Fotherby K
    Contraception; 1993 Jun; 47(6):527-37. PubMed ID: 8334889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
    Letterie GS
    Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ovulation and risk of epithelial ovarian cancer.
    Purdie DM; Bain CJ; Siskind V; Webb PM; Green AC
    Int J Cancer; 2003 Mar; 104(2):228-32. PubMed ID: 12569579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for ovarian cancer: a case-control study.
    Booth M; Beral V; Smith P
    Br J Cancer; 1989 Oct; 60(4):592-8. PubMed ID: 2679848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment.
    Elomaa K; Lähteenmäki P
    Contraception; 1999 Nov; 60(5):275-9. PubMed ID: 10717779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.